Drug Trial News

RSS

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026

Study supports atropine drops for managing childhood short-sightedness

Low concentration atropine eye drops are a safe and effective treatment for short-sightedness (myopia) in UK children, although the effects are small, suggests a clinical trial published by The BMJ today.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

11 Jun 2026

Tranexamic acid reduces surgical transfusions without raising clot risks

A landmark clinical trial published in the prestigious New England Journal of Medicine found that tranexamic acid reduced transfusions across major surgeries without increasing the risk of dangerous blood clots.

10 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Injectable semaglutide may improve fertility outcomes in PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

9 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

Experimental two‑in‑one vaccine shows success in human LASSARAB trial

Researchers from Thomas Jefferson University and the University of Maryland School of Medicine have reported encouraging results from the first human clinical trial of LASSARAB, an experimental vaccine designed to protect against Lassa fever and rabies in a single formulation.

9 Jun 2026

Oral GLP-1 RA reduces blood glucose and bodyweight among people with type 2 diabetes

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight.

8 Jun 2026

Online tool transforms patient experience in national cancer trials

In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP).

8 Jun 2026

Trial shows safety of TTV-guided immunosuppression in kidney transplant recipients

An international research team coordinated by the Medical University of Vienna has demonstrated in a clinical trial that Torque-Teno-virus-guided dosing of immunosuppressants in kidney transplant recipients is safe.

8 Jun 2026

Large clinical trial shows both common septic shock fluids are equal

A randomized clinical trial conducted across five countries in 47 pediatric emergency departments, including Ann & Robert H. Lurie Children's Hospital in Chicago, established that both commonly used IV fluids for treating septic shock – balanced crystalloid fluid and 0.9% saline – are equally safe and effective. Results were published in the New England Journal of Medicine.

5 Jun 2026

Major trials show finerenone preserves kidney function beyond diabetes

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.

5 Jun 2026

Randox Health launches 'RanChip Insights 360'

Randox Health today announces the launch of RanChip Insight 360, an advanced health intelligence programme designed to transform how individuals understand, monitor, and manage their long-term wellbeing.

From Randox Laboratories Ltd. 5 Jun 2026

Common hypertension drugs tied to worse kidney outcomes in T2D patients

New research presented at the 63rd ERA Congress suggests that a widely used class of blood pressure medications may be associated with poorer kidney outcomes in people with type 2 diabetes (T2D), even among patients already receiving modern kidney-protective treatments.

4 Jun 2026

Finerenone slows kidney function decline in non-diabetic patients

The drug finerenone significantly slows the decline in kidney function in patients with chronic kidney disease (CKD) who do not have diabetes.

4 Jun 2026

Universal Sarbeco coronavirus vaccine proves safe in first human trial

The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has shown that the vaccine is safe and has no significant side-effects.

4 Jun 2026

Semaglutide boosts well-being among patients with diabetes and CKD

New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year.

3 Jun 2026